| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CFO | President and CFO
1 company
Andrew Guggenhime is President and CFO at PCVX. Andrew Guggenhime's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.8M at current prices.
Our model assigns Andrew Guggenhime a below-average insider score of 46/100, based on 33 past trades. Over a 12-month horizon, 35.5% of those trades were profitable, with an average 12-month return of -27.5%.
The PCVX filings lean toward selling, a net 284,100 shares.
Andrew Guggenhime has 56 Form 4 filings on record from April 2021 to September 2026, across 2 companies: President and CFO at Vaxcyte (PCVX), 2021–2026; Director at Caribou Biosciences (CRBU), 2021–2026.
The 146 reported transactions were 68 open-market sales, 40 option exercises, 17 tax withholdings and 14 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 32 sales worth about $18.7M.
The largest open-market sale was 42,000 shares of PCVX at an average $115.39 on October 18, 2024, about $4.8M. Twelve months later PCVX was down 63%.
All 21 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | PCVX Vaxcyte, Inc. | President and CFO | Sale+OE10b5-1 | 10,000 | $53.89 | $538,879.35 | -8.7% | - | - | |
| Jul 6, 2026 | PCVX Vaxcyte, Inc. | President and CFO | Sale+OE10b5-1 | 10,000 | $57.28 | $572,836.81 | -8.7% | +29.6% | - | |
| Jun 18, 2026 | PCVX Vaxcyte, Inc. | President and CFO | Sale+OE10b5-1 | 10,000 | $53.00 | $530,000.00 | -8.7% | +14.2% | - | |
| Feb 18, 2025 | PCVX Vaxcyte, Inc. | President and CFO | Sale+OE10b5-1 | 8,000 | $83.85 | $670,822.74 | -6.8% | -61.2% | -31.9% | |
| Jan 21, 2025 | PCVX Vaxcyte, Inc. | President and CFO | Sale+OE10b5-1 | 8,000 | $86.51 | $692,100.57 | -6.8% | -65.5% | -43.0% | |
| Dec 18, 2024 | PCVX Vaxcyte, Inc. | President and CFO | Sale+OE10b5-1 | 8,000 | $88.78 | $710,248.58 | -6.8% | -12.9% | -49.0% | |
| Nov 18, 2024 | PCVX Vaxcyte, Inc. | President and CFO | Sale+OE10b5-1 | 8,000 | $85.81 | $686,517.55 | -6.8% | -4.6% | -42.7% | |
| Oct 18, 2024 | PCVX Vaxcyte, Inc. | President and CFO | Sale+OE10b5-1 | 42,000 | $115.39 | $4,846,508.21 | -31.7% | -24.0% | -63.3% | |
| Sep 18, 2024 | PCVX Vaxcyte, Inc. | President and CFO | Sale+OE10b5-1 | 8,000 | $115.94 | $927,550.51 | -8.1% | -22.9% | -72.0% | |
| Aug 19, 2024 | PCVX Vaxcyte, Inc. | President and CFO | Sale+OE10b5-1 | 8,000 | $78.58 | $628,650.32 | -7.6% | +9.4% | -59.9% |